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Abstract:  Background: In Europe, approximately 381,500 patients are diagnosed with non-small cell lung cancer 
(NSCLC) every year. The aim of this study is to analyse the changes in diagnosis, treatment and evolution during the last 
two decades, using data from a hospital registry. 
Material and Methods: Patients diagnosed with NSCLC at the Corporació Sanitària Parc Taulí-Sabadell (Catalonia, 
Spain) during the periods 1990-1997 (n=748) and 2003-2005 (n=311) were included. The hospital tumour registry was 
used for prospective data collection. 
Results: Our series shows a significant increase in women diagnosed with NSCLC (6% vs 10.3%; p 0.01) in the latter 
period; the incidence of adenocarcinomas increased by 20% (31% vs 51.1%), whereas that of squamous cell carcinomas 
fell (51.3% vs 32.5%; p<0.001). The proportion of patients receiving active treatment also increased significantly, from 
56.6% to 76.5% (p<0.001). Disease stage at diagnosis and the number of patients treated by radical surgical resection 
remained unchanged. Among the favourable independent prognostic factors for survival were: gender (women), age less 
than 70 years old, Karnofsky index 70%, early stage at diagnosis, treatment with chemotherapy, and being diagnosed in 
the latter period 2003-2005 (HR 0.67). Over this 10-year period, absolute gain in mean survival in our series was 115 
days. 
Conclusions: The absolute gain in mean survival in NSCLC patients in the period studied was 3.8 months, with a 6.75% 
increase in 5-year survival. Hospital registry data may help the correct assessment of epidemiological changes and the real 
effectiveness of treatments, which are sometimes overestimated in clinical trials. 
Keywords: Carcinoma, non-small cell lung, registries, mortality, multivariate analysis. 
INTRODUCTION 
  Cancer remains a high-priority public health problem. 
Worldwide prevalence of cancer is around 3% and reaches 
15% at advanced ages [1,2]. Lung and prostate are the 
leading cancer sites among men, and lung is the fourth most 
common among women [3]. In the European Union 381,500 
new cases of lung cancer are diagnosed every year, with   
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341, 800 deaths [4]. Survival rates are low: 30% at one year 
and 10% at five years [5, 6]. Over 16,600 cases of lung 
cancer are diagnosed in Spain every year, accounting for the 
greatest number of cancer deaths [7, 8].
 
  Non-small cell lung cancer (NSCLC) is the most 
common histological type, accounting for 80% of all lung 
cancers. Treatment is determined according to the stage of 
the disease; surgery remains essential in the early stages, 
whereas multimodal treatment with chemotherapy, 
radiotherapy and sometimes surgery is favoured at locally 
advanced stages. Meta-analyses and clinical trials show an 
increase in survival and quality of life with systemic 
palliative chemotherapy for disseminated stages. Despite the 
positive results in survival obtained in patients in clinical 
trials, the real impact on the general population diagnosed The Changing Pattern of Non-Small Cell Lung Cancer  The Open Respiratory Medicine Journal, 2011, Volume 5    25 
with NSCLC seems minor and overall prognosis remains 
poor [5,6,9,10]. 
  The aim of this study was to describe and compare the 
epidemiological, therapeutic and prognostic characteristics 
of patients diagnosed with NSCLC in a north-eastern 
Spanish hospital in the last two decades. The study used our 
centre’s hospital-based cancer registry, an invaluable source 
for assessing the epidemiological factors associated with 
cancer, as well as prognostic variables and outcomes [11].
 
PATIENTS AND METHODS 
 Study  design: Single-centre, prospective, naturalistic, 
open-label, observational study. 
 Setting: Oncology service of the Corporació Sanitària 
Parc Taulí (CSPT), a university hospital affiliated to the 
Universitat Autònoma de Barcelona (UAB) with high 
technological standards and a catchment population of over 
400,000 inhabitants. 
 Sample  size:  As large cell carcinoma is the NSCLC with 
the lowest prevalence (around 10%), for statistical evaluation 
we needed a minimum of 30 patients in this group. We 
therefore required at least 300 patients (n  300) in each 
period. 
 Patient  Recruitment: The hospital thoracic tumour 
registry was used to select all the patients with cytologically 
or histologically-confirmed NSCLC diagnosed from January 
1990 to December 1997 and from January 2003 to December 
2005. Patients were included in the analysis until death or 
last follow-up. 
Study Protocol 
 Registry  variables:  age, sex, histologic subtype and 
grade, tumour stage according to UICC-TNM 5
th ed. 
classification [12], Karnofsky index, type of treatment 
received and death. 
  Patients diagnosed in the first period were reclassified 
according to the 5
th UICC-TNM ed. classification. Both 
Karnofsky index and age were categorised with the usual 
cut-off values. All the variables were recorded prospectively 
except the date of death, which was recorded retrospectively 
from the hospital attendance register and the death records of 
the Health Department of Catalonia. 
 Intervention: All patients were discussed by a 
multidisciplinary institutional committee including the 
various specialists involved: pathologists, medical 
oncologists, radiotherapists, pulmonologists, thoracic 
surgeons and radiologists. Therapeutic decisions were taken 
by consensus of the committee and based on the approved 
clinical guidelines at each moment. 
 Informed  consent: The Internal Review Board (IRB) of 
the Corporació Sanitària Parc Taulí was informed of the data 
collection procedure. Informed consent was considered 
unnecessary because the patients received the habitual 
protocol of treatment, no confidential data were collected, 
and the statistical analyses remained private. 
Statistical Analysis 
  Results are expressed as median (range) and percentages. 
Univariate analysis was performed using the Chi-square test 
to assess associations between categorical variables, and the 
Student ‘t’ test to analyse quantitative variables. Survival 
curves were estimated using Kaplan Meier methods, and the 
log-rank test was used to compare survival between groups 
of patients. Multivariate analysis using the Cox proportional 
hazards model was used to identify independent prognostic 
factors for survival. Adjustments were made for co-variables 
that were clinically relevant or significant in bivariate study. 
Statistical tests were considered significant at p<0.05 (two-
sided). Survival was calculated from date of diagnosis. 
Statistical analysis was performed using SPSS
® 17.0 and 
Stata
® v10.0 packages. 
RESULTS 
  A total of 1,059 patients diagnosed with NSCLC were 
assessed during the two study periods: 748 between 1990 
and 1997 and 311 between 2003 and 2005. Median follow-
up was 13.5 years (3.4-19.5): 14.9 years (11.6-19.5) for 
patients diagnosed during the first period and 5.3 years (3.4-
7.3) for those diagnosed during the second period. 
General Data 
  Our series included 982 men (92.7%) and 77 women 
(7.3%), with a median age at diagnosis of 67.5 years (range 
32-95). Some aspects of NSCLC diagnosed during the two 
periods showed major changes (Table 1). The percentage of 
women diagnosed rose from 6% in the first period to 10.3% 
in the second (p=0.01); the male-to-female ratio fell from 
16:1 in the first period to 9:1 in the second. Furthermore, the 
proportions of squamous cell carcinoma and adenocarcinoma 
changed dramatically between periods. Squamous cell 
histology was predominant in the 1990s, accounting for 
51.3% of cases, while adenocarcinoma was diagnosed in 
31%; in the last decade these figures reversed, with 32.5% 
(p<0.001) of lung cancers diagnosed being squamous cell 
carcinomas and 51.1% adenocarcinomas (p<0.001). Another 
relevant issue is the type of treatment received by patients. In 
the first study period, 44.4% of patients received no 
oncological treatment, whereas between 2003 and 2005 only 
23.5% (p<0.001) received supportive care alone. The 
number of patients receiving chemotherapy doubled (31.4% 
vs 59.8%; p<0.001), although the percentage of patients who 
underwent surgery did not change. No changes were 
observed regarding age of diagnosis or initial tumour stage, 
as the rate of patients diagnosed at locally advanced or 
disseminated stages remained around 75%. 
Survival 
  Median survival of the total group of patients studied 
(n=1,059) was 233 days (7.7 months). One year after 
diagnosis, practically two thirds of the patients had died. 
These figures improved overall during this 10-year period; 
the data collected showed a 12.9% increase in the one-year 
survival rate (32.6% vs 45.5%) and a 6.75% increase at five 
years (8% vs 14.75%). In absolute terms, the median survival 
of patients diagnosed during the first period was 205 days 
(6.7 months) with an increase of 115 days (3.8 months) in 
the second period. Modest to substantial improvements in 
survival were observed for all stages in the second time 
period (Table 2). Fig. (1) shows the survival curve for the 
entire group and differences observed between the two 
periods. 26    The Open Respiratory Medicine Journal, 2011, Volume 5  Montesinos et al. 
Table 2.  Survival 
 
  Global Sv   Sv 1990-97  Sv 2003-05  p Value 
Sv 1 year  36.2% 32,6%  45.5%  0.055 
Sv 5 years  9.9% 8%  14.75%  0.44 
Median Sv (days) 
Stage I-II 
Stage III 
Stage IV 
233 
765 
286 
103 
205 
710 
260 
99 
320 
880 
429 
116 
0.001* 
0,149* 
0,001* 
0,055* 
*Log Rank test p<0.001. 
Abbreviation: Sv: survival. 
 
  Univariate analysis of survival. Differences in survival 
were found in all diagnosed patients when comparing stages 
at diagnosis (p<0.001). Median survival was 765 days at 
initial stages (IA-IIB), and 286 days at locally advanced 
stages (IIIA and IIIB), falling to 103 days at advanced 
stages. Patients over 70 years of age at the time of diagnosis 
had a poorer prognosis, with a median survival of 181 days 
vs 261 days in patients of 70 years or younger (p<0.001). No 
differences were observed between sexes (p=0.96). Median 
survival was 314 days for patients with a good performance  
 
status at diagnosis (Karnofsky index 70) and only 84 days 
for those with a Karnofsky index <70 (p<0.001). The median 
survival time was 272 days for patients diagnosed with 
squamous cell carcinoma, 222 days in cases of adenocarci-
noma and 156 days in cases of large cell/undifferentiated 
carcinomas (p=0.002) (Fig. 2). Likewise, median survival 
varied according to the histological differentiation of 
tumour: 524 days for well differentiated cancers (g1), 274 
days for moderately differentiated ones (g2), and 248 days 
for poorly differentiated ones (g3), (p=0.3). Finally, patients 
treated with chemotherapy had a longer survival (328 days) 
than those who did not (155 days; p <0.001). 
  Multivariate analysis of survival.  Clinically relevant or 
statistically significant variables for univariate analysis were 
included in a multivariate Cox regression analysis. Sex, age, 
Karnofsky index, histology, stage, chemotherapy and period 
of diagnosis were identified as independent prognostic 
factors for survival (Table 3). 
  The analysis showed that males have a worse prognosis 
than females (HR 1.37; p=0.02) and that age over 70 years 
per se also worsened prognosis (HR 1.21; p=0.01). A good 
performance status at diagnosis with a Karnofsky index 70 
was linked to better survival (HR 0.43; p<0.001). Histo-   
 
Table 1.  Comparison of General Data Between the Two Periods 
 
  1990-1997 (n =748)  2003-2005 (n=311)  p Value 
Age (Median; range)  67 (32-91)  68 (33-95)  ns 
Sex  
Male 
Female 
 
703 (94%) 
45 (6%) 
 
279 (89.7%) 
32 (10.3%) 
 
p 0.014 
Histology  
Squamous cell Ca 
Adenocarcinoma 
L. Cell/Undifferentiated 
Unknown 
 
384 (51.3%) 
232 (31%) 
106 (14.2%) 
26 (3.5%) 
 
101 (32.5%) 
159 (51.1%) 
41 (13.2%) 
10 (3.2%) 
 
p<0.001 
p<0.001 
ns 
ns 
Differentiation  
Grade I 
Grade II 
Grade III 
Unknown 
 
16 (2.1%) 
116 (15.5%) 
233 (31.1%) 
383 (51.2%) 
 
9 (2.9%) 
38 (12.2%) 
135 (43.4%) 
129(41.5%) 
 
ns 
ns 
p<0.001 
p 0.004 
Stage  
Ia 
Ib 
IIa 
IIb 
IIIa 
IIIb 
IV 
Unknown 
 
43 (5.7%) 
70 (9.4%) 
0 
42 (5.6%) 
44 (5.9%) 
155 (20.7%) 
276 (36.9%) 
118 (15.8%) 
 
31 (10%) 
21 (6.8%) 
8 (2.6%) 
18 (5.8%) 
28 (9%) 
86 (27.7%) 
116 (37.3%) 
3 (1%) 
 
ns 
Treatment 
Supportive care 
Surgery 
Chemotherapy 
Radiotherapy 
 
332 (44.4%) 
167 (22.3%) 
235 (31.4%) 
151 (20.2%) 
 
73 (23.5%) 
63 (20.2%) 
186 (59.8%) 
120 (38.7%) 
 
p<0.001 
ns 
p<0.001 
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Fig. (1). Overall survival and survival by period of diagnosis. 
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(Fig. 2) contd….. 
 
 
Fig. (2). Survival curves by gender, age, tumour stage, histology 
and Karnofsky index. 
logically, only the subgroup of large cell or undifferentiated 
carcinomas presents a risk of death higher than the reference 
(in this case, squamous cell carcinomas - 1.24 times higher, 
p=0.05). One of the factors with the greatest impact on 
survival is the stage of the disease at diagnosis. Taking 
localised stages as a reference, the risk of death increased 2.5 
times (p<0.001) when the disease was diagnosed at stage III, 
and up to 5.2 times (p<0.001) if diagnosed at stage IV. 
Administration of chemotherapy also lowers the risk of death 
(HR 0.7; p<0.001). Lastly, we observed that patients 
diagnosed with NSCLC during the second period (2003-
2005) survived longer than those diagnosed during the first 
(HR 0.67; p<0.001). 
DISCUSSION 
  Using data from patients diagnosed with NSCLC at our 
centre during the two periods 1990-1997 and 2003-2005, we 
assessed changes in epidemiology, characteristics of 
tumours, and treatments administered. We also analysed the 
differences in survival between the two groups. 
 
Table 3.  Cox Multivariate Regression Model 
 
Variable Hazard  Ratio  95% CI  p Value 
Age  
70 
>70  
 
1
c 
1.219 
-- 
1.039 to 1.430 
 
-- 
0.015 
Sex  
Female 
Male 
 
1
c 
1.377 
 
-- 
1.041 to 1.821 
 
-- 
0.025 
Karnofsky Index  
<70 
 70 
 
1
c 
0.439 
 
-- 
0.361 to 0.534 
 
-- 
<0.001 
Histology  
Squamous cell Ca 
Adenocarcinoma 
Large cell/Undifferentiated 
 
1
c 
1.058 
1.240 
 
-- 
0.899 to 1.245 
1.000 to 1.537 
  
-- 
0.499 
0.05 
Stage  
Ia-IIb 
IIIa-IIIb 
IV 
 
1
c 
2.550 
5.283 
 
-- 
2.058 to 3.158 
4.281 to 6.520 
 
-- 
<0.001 
<0.001 
Chemotherapy  
No 
Yes  
 
1
c 
0.706 
 
-- 
0.591 to 0,843 
 
-- 
<0.001 
Period  
1990-97 
2003-05 
 
1
c 
0.670 
 
-- 
0.563 to 0.797 
 
-- 
<.001 
Cases available in analysis: 865 (81.2%). 
c Reference category. 
 
  Patients’ information was obtained from the hospital 
tumour registry, a reliable source that provides data on all 
variables. We compared these two time periods because 
treatments administered in each one were reasonably 
homogeneous, with no significant changes in the therapeutic 
approach inside each period. Although the number of 
patients included was higher in the first period, the sample 
size requirements were met. A meta-analysis published in 
1995, demonstrating a significant but modest survival benefit 
of chemotherapy compared with supportive care alone in 
patients with advanced NSCLC [9], led to an important 
change in strategy and in the late 1990s combinations with 
newer third-generation cytotoxic drugs improved response 
rate and survival. In the last decade new drugs have been 
developed for specific biological pathways, offering 
increased specificity and reduced toxicity. Trial BR21, 
published in 2005, proved that erlotinib, an oral tyrosine 
kinase inhibitor for epidermal growth factor receptor, 
improved overall survival compared with placebo in 
previously treated patients with NCSLC [19]. Below we 
discuss the influence of the different treatments in the 
population analysed. 
  Our study detected a significant increase in the 
percentage of women diagnosed with lung cancer in recent 
years. The causal relationship with smoking is obvious and 
this upward trend is comparable to countries where women 
started smoking earlier, such as the United States. In fact, 
incidence and mortality rate for lung cancer amongst men 
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has fallen, while it has increased for women [13]. According 
to data obtained from a National Health Survey performed in 
Spain in 1993, 44% of adult men smoked, compared with 
20.8% of women; by 2006, tobacco consumption had 
dropped to 31.6% in men and increased to around 21.5% in 
women. Regarding survival rates according to sex, our study 
shows that men present a moderately worse prognosis than 
women, independent of other variables (HR 1.37). Other 
registries such as the SEER in the US [13] and others in 
Japan [14] have also found higher percentages of 5-year 
survival in women than in men (around 5%), and the 
Eurocare-4 project reported better prognosis for women in 
most cancers except for tumours of the biliary tract, larynx, 
and urinary bladder [6]. The excess risk of death for males is 
1.05 (95% CI: 1.04, 1.05) [15]. The reasons why women 
have a better prognosis than men are unknown: comorbidity 
factors, biological advantages or cultural factors such as 
better compliance with treatment, follow-up and physicians’ 
indications have been suggested as possible causes [16]. 
  Dramatic changes in the histology of non-small cell lung 
cancer have been recorded in the past two decades. The 
incidence of squamous cell carcinomas has decreased by 
30%, while that of adenocarcinomas has risen in the US, 
Canada, Australia, the Netherlands and elsewhere. The 
SEER data in the US (2002-2006) [13] show that of all lung 
cancers, 14% correspond to small cell, 19.9% to squamous 
cell carcinomas, 36.9% to adenocarcinomas, 3.5% to large 
cell and 24.6% to other types. Similar trends have been 
observed in most developed countries. No such change had 
been noted in Spain in the year 2000 [17], but our series 
shows a striking change between our two time periods; the 
proportion of squamous cell carcinomas had fallen by 20% 
in the 2003-2005 period, whereas adenocarcinomas had 
increased by the same amount. The reasons for this change 
in the histopathology of NSCLC seem to be related to 
tobacco consumption, which causes 90% of diagnosed lung 
cancers. Changes in smoking habits, with Virginia tobacco 
gradually replacing dark tobacco and filtered cigarettes 
gradually replacing unfiltered ones, and changes in the 
composition of certain brands with a reduction in polycyclic 
aromatic hydrocarbons and an increase in N-nitrosamines 
seem to be the cause of this variation in the histopathology 
of lung cancer in such a short period [16, 17]. 
  Therapeutic strategy also underwent a notable change 
during this time period. The results of comparative trials and 
meta-analyses performed in the mid-1990s argued in favour 
of the use of chemotherapy instead of supportive care and by 
the year 2000, the publication of trials with second-line 
antitumour treatments gave further support to the change in 
therapeutic approach [9,10,18,19]. Our study shows that over 
the two periods the proportions of chemotherapy and 
radiotherapy increased by 30% and 20% respectively, 
whereas surgery has remained stable. Fifteen years ago, 
44.4% of patients in our series received only supportive care, 
but this figure dropped to 23% in 2003-2005. The use of 
oncological treatments in patients who performed well in the 
first trials increased survival by more than two months for 
both the first and the second line of treatment. The 
introduction of new target therapies seems to maintain this 
tendency. 
  Population- and hospital-based registries include many 
patients who would not have been included in clinical trials 
for personal or disease-related reasons. Thus, one should be 
cautious when extrapolating the results of clinical trials to 
the general population diagnosed with NSCLC. Further 
studies like this one are necessary to assess the real 
effectiveness of treatments and the evolution of cancer 
control measures, and are made far easier if a hospital-based 
registry is in place. 
  Our study shows that the difference in overall survival in 
the two periods of time was 115 days (3.8 months); 1-year 
survival increased from 32.6% to 45.5% and 5-year survival 
from 8% to 14.75%. These figures are comparable with 
those obtained in neighbouring countries. Eurocare-4 (1995-
1999) [6] reported a 1-year survival of 36% and a 5-year 
survival of 12%. In Spain, Eurocare-4 showed survival rates 
at 1 and 5 years of 34.2 and 10.2% respectively. When 
reviewing the tendency towards increased survival in 
population registries, we observe that 5-year survival (e.g., in 
the United States) has risen from 13.8% in 1990 to 16.2% in 
2000, which represents an increase of less than 2.5% in 
patients alive at 5 years [20]. 
  Some limitations should be borne in mind when 
extrapolating our findings to other medical centres. The 
demographic, social and economic characteristics of the 
population should be taken into consideration, as should 
differences in accessibility and in the availability of 
technological resources at each hospital. The reference 
population of our sample was predominantly from the urban 
and industrial area of Barcelona. During the study period, 
patients’ fidelity to their reference hospital was high and the 
medical and surgical team remained stable. As this is a 
teaching hospital with extensive experience in treating such 
patients and promoting research, we consider that the data 
obtained in our study may be representative of other areas in 
Spain as well as neighbouring countries. 
  Another important limitation in our study is that the 
degree of tobacco consumption of patients is not reflected. 
This information was initially recorded as number of packet-
cigarettes/day and then as packets/year, so it is difficult to 
compare the two periods. 
  Despite the advances in recent years, lung cancer remains 
the leading cause of cancer deaths. Treatments should be 
improved and primary prevention of smoking promoted to 
increase the modest survival benefits described. Hospital 
tumour registries provide very useful information to 
complement that obtained from experimental clinical 
research studies and population-based registries 
[6,13,14,21,22] and provide a broader picture of the trends in 
the control of malignant diseases. 
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